380 related articles for article (PubMed ID: 29442276)
21. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma.
Hiraoka A; Kumada T; Michitaka K; Toyoda H; Tada T; Ueki H; Kaneto M; Aibiki T; Okudaira T; Kawakami T; Kawamura T; Yamago H; Suga Y; Miyamoto Y; Tomida H; Azemoto N; Mori K; Miyata H; Ninomiya T; Kawasaki H
J Gastroenterol Hepatol; 2016 May; 31(5):1031-6. PubMed ID: 26647219
[TBL] [Abstract][Full Text] [Related]
22. Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment.
Hu K; Yuan J; Tang B; Zhang F; Lu S; Chen R; Zhang L; Ren Z; Yin X
Ann Transl Med; 2021 Feb; 9(3):237. PubMed ID: 33708864
[TBL] [Abstract][Full Text] [Related]
23. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
[TBL] [Abstract][Full Text] [Related]
24. Albumin-Bilirubin Score: An Accurate Predictor of Hepatic Decompensation in High-Risk Patients Undergoing Transarterial Chemoembolization for Hepatocellular Carcinoma.
Mohammed MAA; Khalaf MH; Liang T; Wang DS; Lungren MP; Rosenberg J; Kothary N
J Vasc Interv Radiol; 2018 Nov; 29(11):1527-1534.e1. PubMed ID: 30274856
[TBL] [Abstract][Full Text] [Related]
25. A New Prognostic Model Based on Albumin-Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria.
Ho SY; Liu PH; Hsu CY; Hsia CY; Huang YH; Su CW; Lei HJ; Lee RC; Hou MC; Huo TI
Dig Dis Sci; 2020 Feb; 65(2):658-667. PubMed ID: 31659612
[TBL] [Abstract][Full Text] [Related]
26. Comparison Between Child-Turcotte-Pugh and Albumin-Bilirubin Scores in Assessing the Prognosis of Hepatocellular Carcinoma After Stereotactic Ablative Radiation Therapy.
Lo CH; Liu MY; Lee MS; Yang JF; Jen YM; Lin CS; Chao HL; Shen PC; Huang WY
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):145-152. PubMed ID: 28816140
[TBL] [Abstract][Full Text] [Related]
27. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.
Izumoto H; Hiraoka A; Ishimaru Y; Murakami T; Kitahata S; Ueki H; Aibiki T; Okudaira T; Miyamoto Y; Yamago H; Iwasaki R; Tomida H; Mori K; Kishida M; Tsubouchi E; Miyata H; Ninomiya T; Kawasaki H; Hirooka M; Matsuura B; Abe M; Hiasa Y; Michitaka K; Kudo M
Oncology; 2017; 93 Suppl 1():120-126. PubMed ID: 29258105
[TBL] [Abstract][Full Text] [Related]
28. ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era.
Liu PH; Hsu CY; Hsia CY; Lee YH; Chiou YY; Huang YH; Lee FY; Lin HC; Hou MC; Huo TI
J Gastroenterol Hepatol; 2017 Apr; 32(4):879-886. PubMed ID: 27696519
[TBL] [Abstract][Full Text] [Related]
29. Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis B-associated hepatocellular carcinoma.
Chan AW; Chong CC; Mo FK; Wong J; Yeo W; Johnson PJ; Yu S; Lai PB; Chan AT; To KF; Chan SL
J Gastroenterol Hepatol; 2016 Oct; 31(10):1766-1772. PubMed ID: 26992142
[TBL] [Abstract][Full Text] [Related]
30. Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma.
Chan AW; Kumada T; Toyoda H; Tada T; Chong CC; Mo FK; Yeo W; Johnson PJ; Lai PB; Chan AT; To KF; Chan SL
J Gastroenterol Hepatol; 2016 Jul; 31(7):1300-6. PubMed ID: 26751608
[TBL] [Abstract][Full Text] [Related]
31. Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early/early stage of hepatocellular carcinoma.
Chong CC; Chan AW; Wong J; Chu CM; Chan SL; Lee KF; Yu SC; To KF; Johnson P; Lai PB
Surgeon; 2018 Jun; 16(3):163-170. PubMed ID: 28807570
[TBL] [Abstract][Full Text] [Related]
32. NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization.
Adhoute X; Pénaranda G; Raoul JL; Bollon E; Pol B; Letreut YP; Perrier H; Bayle O; Monnet O; Beaurain P; Muller C; Hardwigsen J; Lefolgoc G; Castellani P; Bronowicki JP; Bourlière M
Eur J Gastroenterol Hepatol; 2017 Jun; 29(6):706-715. PubMed ID: 28195873
[TBL] [Abstract][Full Text] [Related]
33. Albumin-bilirubin versus Child-Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma.
Wang YY; Zhong JH; Su ZY; Huang JF; Lu SD; Xiang BD; Ma L; Qi LN; Ou BN; Li LQ
Br J Surg; 2016 May; 103(6):725-734. PubMed ID: 27005482
[TBL] [Abstract][Full Text] [Related]
34. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
Lee PC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lee MH; Hou MC; Lee FY; Lin HC; Huang YH
Liver Int; 2018 Feb; 38(2):321-330. PubMed ID: 28736952
[TBL] [Abstract][Full Text] [Related]
35. Application of the albumin-bilirubin grade for predicting prognosis after curative resection of patients with early-stage hepatocellular carcinoma.
Ma XL; Zhou JY; Gao XH; Tian L; Wu J; Zhang CY; Zhou Y; Dai Q; Wang BL; Pan BS; Yang XR; Guo W
Clin Chim Acta; 2016 Nov; 462():15-22. PubMed ID: 27520748
[TBL] [Abstract][Full Text] [Related]
36. Albumin-bilirubin grade-based nomogram of the BCLC system for personalized prognostic prediction in hepatocellular carcinoma.
Ho SY; Hsu CY; Liu PH; Hsia CY; Lei HJ; Huang YH; Ko CC; Su CW; Lee RC; Hou MC; Huo TI
Liver Int; 2020 Jan; 40(1):205-214. PubMed ID: 31505104
[TBL] [Abstract][Full Text] [Related]
37. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.
Zhou DS; Xu L; Luo YL; He FY; Huang JT; Zhang YJ; Chen MS
World J Gastroenterol; 2015 May; 21(18):5582-90. PubMed ID: 25987783
[TBL] [Abstract][Full Text] [Related]
38. Modified Child-Pugh grade
Huang F; Gao J
World J Gastroenterol; 2020 Feb; 26(7):749-758. PubMed ID: 32116422
[TBL] [Abstract][Full Text] [Related]
39. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma.
Hucke F; Pinter M; Graziadei I; Bota S; Vogel W; Müller C; Heinzl H; Waneck F; Trauner M; Peck-Radosavljevic M; Sieghart W
J Hepatol; 2014 Dec; 61(6):1287-96. PubMed ID: 25016222
[TBL] [Abstract][Full Text] [Related]
40. ASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization.
Jia KF; Wang H; Yu CL; Yin WL; Zhang XD; Wang F; Sun C; Shen W
Hepatobiliary Pancreat Dis Int; 2023 Oct; 22(5):490-497. PubMed ID: 35260337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
